Citations (62)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Cecilia M. Rodriguez, Claudio Bussi, Daniela S. Arroyo, Dario Sastre, Viviana Heller, Carmen Stanganelli, Irma Slavutsky & Pablo Iribarren. (2019) Effects of rapamycin in combination with fludarabine on primary chronic lymphocytic leukemia cells. Leukemia & Lymphoma 60:5, pages 1299-1303.
Read now
Read now
Ayed O. Ayed & Sameer A. Parikh. (2018) Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy. Leukemia & Lymphoma 59:10, pages 2287-2296.
Read now
Read now
Mitchell Evers, Margot Jak & J. H. W. Leusen. (2018) The latest developments with anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia. Expert Opinion on Biological Therapy 18:9, pages 973-982.
Read now
Read now
Benjamin L. Lampson & Jennifer R. Brown. (2018) Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?. Expert Review of Hematology 11:3, pages 185-194.
Read now
Read now
Minhang Xin, Weiming Duan, Yifan Feng, Yuan-Yuan Hei, Hao Zhang, Ying Shen, Hong-Yi Zhao, Shuai Mao & San-Qi Zhang. (2018) Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3Kδ) inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry 33:1, pages 651-656.
Read now
Read now
Kyle Crassini, Yandong Shen, Stephen Mulligan & O. Giles Best. (2017) Modeling the chronic lymphocytic leukemia microenvironment in vitro. Leukemia & Lymphoma 58:2, pages 266-279.
Read now
Read now
Yazan F Madanat, Mitchell R Smith, Alexandru Almasan & Brian T Hill. (2016) Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas. Blood and Lymphatic Cancer: Targets and Therapy 6, pages 1-6.
Read now
Read now
Raul Cordoba, Margarita Sanchez-Beato, Beatriz Herreros, Elena Domenech, Jose Garcia-Marco, Juan-F Garcia, Joaquin Martinez-Lopez, Antonia Rodriguez, Aranzazu Garcia-Raso, Pilar Llamas & Miguel-Angel Piris. (2016) Two distinct molecular subtypes of chronic lymphocytic leukemia give new insights on the pathogenesis of the disease and identify novel therapeutic targets. Leukemia & Lymphoma 57:1, pages 134-142.
Read now
Read now
Filippa Pettersson, Sonia V del Rincon & Wilson H Miller$suffix/text()$suffix/text(). (2014) Eukaryotic translation initiation factor 4E as a novel therapeutic target in hematological malignancies and beyond. Expert Opinion on Therapeutic Targets 18:9, pages 1035-1048.
Read now
Read now
Ting-Ting Han, Lei Fan, Jian-Yong Li & Wei Xu. (2014) Role of chemokines and their receptors in chronic lymphocytic leukemia. Cancer Biology & Therapy 15:1, pages 3-9.
Read now
Read now
Mohammed ZH Farooqui & Adrian Wiestner. (2013)
Ibrutinib for the treatment of chronic lymphocytic leukemia. Expert Opinion on Orphan Drugs 1:11, pages 925-933.
Read now
Read now
Julio C Chavez, Eva Sahakian & Javier Pinilla-Ibarz. (2013) Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia. Core Evidence 8, pages 37-45.
Read now
Read now
Matthew S. Davids, Anthony Letai & Jennifer R. Brown. (2013) Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition. Leukemia & Lymphoma 54:8, pages 1823-1825.
Read now
Read now
Tadeusz Robak & Pawel Robak. (2013) BCR Signaling in Chronic Lymphocytic Leukemia and Related Inhibitors Currently in Clinical Studies. International Reviews of Immunology 32:4, pages 358-376.
Read now
Read now
Articles from other publishers (48)
Deepti Gadi, Stephen P. Martindale, Pui Yan Chiu, Jasneet Khalsa, Pei-Hsuan Chen, Stacey M. Fernandes, Zixu Wang, Svitlana Tyekucheva, John-Hanson Machado, David C. Fisher, Philippe Armand, Matthew S. Davids, Scott Rodig, Barbara Sherry & Jennifer R. Brown. (2023) Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors. Blood Cancer Journal 13:1.
Crossref
Crossref
Shuaikang Chang, Bo Li, Yongsheng Xie, Yingcong Wang, Zhijian Xu, Shuhan Jin, Dandan Yu, Huaping Wang, Yumeng Lu, Yong Zhang, Ruye Ma, Cheng Huang, Weiming Lai, Xiaosong Wu, Weiliang Zhu & Jumei Shi. (2022) DCZ0014, a novel compound in the therapy of diffuse large B-cell lymphoma via the B cell receptor signaling pathway. Neoplasia 24:1, pages 50-61.
Crossref
Crossref
Sunil K. Noothi, Mary K. McKenna, Sara S. Alhakeem, James P. Collard, J. T. Greene, Natarajan Muthusamy, Vivek M. Rangnekar & Subbarao Bondada. 2021. Tumor Suppressor Par-4. Tumor Suppressor Par-4
133
148
.
Gareth S.D. Purvis, Massimo Collino, Haidee Aranda‐Tavio, Fausto Chiazza, Caroline E. O'Riordan, Lynda Zeboudj, Shireen Mohammad, Debora Collotta, Roberta Verta, Nicolas E.S. Guisot, Peter Bunyard, Magdi M. Yaqoob, David R. Greaves & Christoph Thiemermann. (2020) Inhibition of Bruton's TK regulates macrophage NF‐κB and NLRP3 inflammasome activation in metabolic inflammation. British Journal of Pharmacology 177:19, pages 4416-4432.
Crossref
Crossref
Jiajia Sun, Yifan Feng, Yuan Huang, San-Qi Zhang & Minhang Xin. (2020) Research advances on selective phosphatidylinositol 3 kinase δ (PI3Kδ) inhibitors. Bioorganic & Medicinal Chemistry Letters 30:19, pages 127457.
Crossref
Crossref
Nathan Dubois, Emerence Crompot, Nathalie Meuleman, Dominique Bron, Laurence Lagneaux & Basile Stamatopoulos. (2020) Importance of Crosstalk Between Chronic Lymphocytic Leukemia Cells and the Stromal Microenvironment: Direct Contact, Soluble Factors, and Extracellular Vesicles. Frontiers in Oncology 10.
Crossref
Crossref
Simar Pal Singh, Marjolein J. W. de Bruijn, Catarina Velaso Gago da Graça, Odilia B. J. Corneth, Jasper Rip, Ralph Stadhouders, Ruud W. J. Meijers, Stéphane Schurmans, William G. Kerr, Johanna ter Burg, Eric Eldering, Anton W. Langerak, Saravanan Y. Pillai & Rudi W. Hendriks. (2020) Overexpression of SH2-Containing Inositol Phosphatase Contributes to Chronic Lymphocytic Leukemia Survival. The Journal of Immunology 204:2, pages 360-374.
Crossref
Crossref
Edgar Márquez, José R. Mora, Virginia Flores-Morales, Daniel Insuasty & Luis Calle. (2019) Modeling the Antileukemia Activity of Ellipticine-Related Compounds: QSAR and Molecular Docking Study. Molecules 25:1, pages 24.
Crossref
Crossref
Yue Wen, Yukai Jing, Lu Yang, Danqing Kang, Panpan Jiang, Na Li, Jiali Cheng, Jingwen Li, Xingbo Li, Zican Peng, Xizi Sun, Heather Miller, Zhiwei Sui, Quan Gong, Boxu Ren, Wei Yin & Chaohong Liu. (2019) The regulators of BCR signaling during B cell activation. Blood Science 1:2, pages 119-129.
Crossref
Crossref
Matthew S Davids, Haesook T Kim, Alyssa Nicotra, Alexandra Savell, Karen Francoeur, Jeffrey M Hellman, Josie Bazemore, Hari P Miskin, Peter Sportelli, Laura Stampleman, Rodrigo Maegawa, Jens Rueter, Adam M Boruchov, Jon E Arnason, Caron A Jacobson, Eric D Jacobsen, David C Fisher & Jennifer R Brown. (2019) Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study. The Lancet Haematology 6:1, pages e38-e47.
Crossref
Crossref
Minhang Xin, Weiming Duan, Yifan Feng, Yuan-Yuan Hei, Hao Zhang, Ying Shen, Hong-Yi Zhao, Shuai Mao & San-Qi Zhang. (2018) Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3Kδ) inhibitors. Bioorganic & Medicinal Chemistry 26:8, pages 2028-2040.
Crossref
Crossref
Paula Cramer, Julia von Tresckow, Jasmin Bahlo, Anja Engelke, Petra Langerbeins, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Stephan Stilgenbauer, Sebastian Böttcher, Barbara Eichhorst & Michael Hallek. (2018) CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Future Oncology 14:6, pages 499-513.
Crossref
Crossref
Prabhjot KaurPrabhjot Kaur. 2018. Chronic Lymphocytic Leukemia. Chronic Lymphocytic Leukemia
61
89
.
Natália Aydos Marcondes, Flavo Beno Fernandes, Ana Paula Alegretti & Gustavo Adolpho Moreira Faulhaber. (2016) Expression of Bruton’s tyrosine kinase in B-cell neoplasms evaluated by flow cytometry. Clinical and Experimental Medicine 17:4, pages 499-504.
Crossref
Crossref
Monika Podhorecka, Aneta Goracy, Agnieszka Szymczyk, Malgorzata Kowal, Blanca Ibanez, Olga Jankowska-Lecka, Arkadiusz Macheta, Aleksandra Nowaczynska, Elzbieta Drab-Urbanek, Sylwia Chocholska, Dariusz Jawniak & Marek Hus. (2017) Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number. Oncotarget 8:21, pages 34661-34669.
Crossref
Crossref
Minhang Xin, Yuan-Yuan Hei, Hao Zhang, Ying Shen & San-Qi Zhang. (2017) Design and synthesis of novel 6-aryl substituted 4-anilinequinazoline derivatives as potential PI3Kδ inhibitors. Bioorganic & Medicinal Chemistry Letters 27:9, pages 1972-1977.
Crossref
Crossref
Yueyu Cao, Jing Qiao, Zhen Lin, Jovanny Zabaleta, Lu Dai & Zhiqiang Qin. (2017) Up-regulation of tumor suppressor genes by exogenous dhC16-Cer contributes to its anti-cancer activity in primary effusion lymphoma. Oncotarget 8:9, pages 15220-15229.
Crossref
Crossref
Sina OppermannJarkko YlankoYonghong ShiSantosh HariharanChristopher C. OakesPatrick M. BrauerJuan C. Zúñiga-PflückerBrian LeberDavid E. Spaner & David W. Andrews. (2016) High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells. Blood 128:7, pages 934-947.
Crossref
Crossref
Jennifer R. Brown. (2016) The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia. Seminars in Oncology 43:2, pages 260-264.
Crossref
Crossref
Michael T. Tees & Lubomir Sokol. (2016) Novel Pharmacotherapies for B-Cell Lymphomas and Leukemias. American Journal of Therapeutics 23:2, pages e498-e520.
Crossref
Crossref
Paula Cramer, Barbara Eichhorst, Hans Christian Reinhardt & Michael Hallek. (2016) Current strategies to create tailored and risk-adapted therapies for CLL patients. Best Practice & Research Clinical Haematology 29:1, pages 111-121.
Crossref
Crossref
Michael Y. Choi, Manoj Kumar Kashyap & Deepak Kumar. (2016) The chronic lymphocytic leukemia microenvironment: Beyond the B-cell receptor. Best Practice & Research Clinical Haematology 29:1, pages 40-53.
Crossref
Crossref
Paula Cramer, Petra Langerbeins, Barbara Eichhorst & Michael Hallek. (2016) Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG). European Journal of Haematology 96:1, pages 9-18.
Crossref
Crossref
Paula Cramer, Petra Langerbeins & Michael Hallek. (2016) Combination of Targeted Drugs to Control Chronic Lymphocytic Leukemia. The Cancer Journal 22:1, pages 62-66.
Crossref
Crossref
X Cui, L Zhang, A R Magli, R Catera, X-J Yan, D O Griffin, T L Rothstein, J Barrientos, J E Kolitz, S L Allen, K R Rai, N Chiorazzi & C C Chu. (2015) Cytoplasmic myosin-exposed apoptotic cells appear with caspase-3 activation and enhance CLL cell viability. Leukemia 30:1, pages 74-85.
Crossref
Crossref
James Shen & Kevin R. Kelly. 2016. mTOR Inhibition for Cancer Therapy: Past, Present and Future. mTOR Inhibition for Cancer Therapy: Past, Present and Future
139
160
.
Susan M. O'BrienNicole LamannaThomas J. KippsIan FlinnAndrew D. ZelenetzJan A. BurgerMichael KeatingSiddhartha Mitra, Leanne Holes, Albert S. Yu, David M. Johnson, Langdon L. Miller, Yeonhee Kim, Roger D. Dansey, Ronald L. Dubowy & Steven E. Coutre. (2015) A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood 126:25, pages 2686-2694.
Crossref
Crossref
Matthew D. BluntMatthew J. CarterMarta LarrayozLindsay D. SmithMaria Aguilar-HernandezKerry L. CoxThomas TiptonMark ReynoldsSarah MurphyElizabeth LemmSamantha DiasAndrew Duncombe, Jonathan C. StreffordPeter W. M. JohnsonFrancesco Forconi, Freda K. StevensonGraham PackhamMark S. CraggAndrew J. Steele. (2015) The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model. Blood 125:26, pages 4032-4041.
Crossref
Crossref
R Mani, Y Mao, F W Frissora, C-L Chiang, J Wang, Y Zhao, Y Wu, B Yu, R Yan, X Mo, L Yu, J Flynn, J Jones, L Andritsos, S Baskar, C Rader, M A Phelps, C-S Chen, R J Lee, J C Byrd, L J Lee & N Muthusamy. (2014) Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia. Leukemia 29:2, pages 346-355.
Crossref
Crossref
Nadine KutschReinhard MarksRichard RateiThomas K. HeldMartin Schmidt-Hieber. (2015) Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms. Biomarker Insights 10s3, pages BMI.S22434.
Crossref
Crossref
S E M Herman, C U Niemann, M Farooqui, J Jones, R Z Mustafa, A Lipsky, N Saba, S Martyr, S Soto, J Valdez, J A Gyamfi, I Maric, K R Calvo, L B Pedersen, C H Geisler, D Liu, G E Marti, G Aue & A Wiestner. (2014) Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia 28:11, pages 2188-2196.
Crossref
Crossref
Jessica A. Gasser, Hiroyuki Inuzuka, Alan W. Lau, Wenyi Wei, Rameen Beroukhim & Alex Toker. (2014) SGK3 Mediates INPP4B-Dependent PI3K Signaling in Breast Cancer. Molecular Cell 56:4, pages 595-607.
Crossref
Crossref
Mercedes Borge, Federico Remes Lenicov, Paula R. Nannini, María M. de los Ríos Alicandú, Enrique Podaza, Ana Ceballos, Horacio Fernández Grecco, María Cabrejo, Raimundo F. Bezares, Pablo E. Morande, Pablo Oppezzo, Mirta Giordano & Romina Gamberale. (2014) The Expression of Sphingosine-1 Phosphate Receptor-1 in Chronic Lymphocytic Leukemia Cells Is Impaired by Tumor Microenvironmental Signals and Enhanced by Piceatannol and R406. The Journal of Immunology 193:6, pages 3165-3174.
Crossref
Crossref
Arishya Sharma, Allison J. Janocha, Brian T. Hill, Mitchell R. Smith, Serpil C. Erzurum & Alexandru Almasan. (2014) Targeting mTORC1–Mediated Metabolic Addiction Overcomes Fludarabine Resistance in Malignant B Cells. Molecular Cancer Research 12:9, pages 1205-1215.
Crossref
Crossref
Amin Aalipour & Ranjana H. Advani. (2014) Bruton’s tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. Therapeutic Advances in Hematology 5:4, pages 121-133.
Crossref
Crossref
Freda K. Stevenson, Francesco Forconi & Graham Packham. (2014) The Meaning and Relevance of B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia. Seminars in Hematology 51:3, pages 158-167.
Crossref
Crossref
Matthew S. Davids. (2014) Boldly Targeting Kinases without mutations. Blood 123:8, pages 1119-1121.
Crossref
Crossref
Jennifer R Brown. (2014) A new era of treatment for chronic lymphocytic leukaemia?. The Lancet Oncology 15:1, pages 3-5.
Crossref
Crossref
Carsten U. Niemann & Adrian Wiestner. (2013) B-cell receptor signaling as a driver of lymphoma development and evolution. Seminars in Cancer Biology 23:6, pages 410-421.
Crossref
Crossref
Amin Aalipour & Ranjana H. Advani. (2013) Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas. British Journal of Haematology 163:4, pages 436-443.
Crossref
Crossref
P Oppezzo & G Dighiero. (2013) “Role of the B-cell receptor and the microenvironment in chronic lymphocytic leukemia’’. Blood Cancer Journal 3:9, pages e149-e149.
Crossref
Crossref
Antonino Carbone & Anas YounesPiers EM PattenCharles C ChuNicholas Chiorazzi. 2013. Non-Hodgkin Lymphomas: Advanced Diagnostics & Personalized Therapies. Non-Hodgkin Lymphomas: Advanced Diagnostics & Personalized Therapies
196
214
.
Yair Herishanu, Ben-Zion Katz, Andrew Lipsky & Adrian Wiestner. (2013) Biology of Chronic Lymphocytic Leukemia in Different Microenvironments. Hematology/Oncology Clinics of North America 27:2, pages 173-206.
Crossref
Crossref
Jennifer R. Brown. (2013) Ibrutinib (PCI-32765), the First BTK (Bruton’s Tyrosine Kinase) Inhibitor in Clinical Trials. Current Hematologic Malignancy Reports 8:1, pages 1-6.
Crossref
Crossref
Dan A Landau & Catherine J Wu. (2013) Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics. Genome Medicine 5:5, pages 47.
Crossref
Crossref
Valentina Audrito, Tiziana Vaisitti, Sara Serra, Cinzia Bologna, Davide Brusa, Fabio Malavasi & Silvia Deaglio. (2013) Targeting the microenvironment in chronic lymphocytic leukemia offers novel therapeutic options. Cancer Letters 328:1, pages 27-35.
Crossref
Crossref
Rita Shaknovich. 2013. Advances in Chronic Lymphocytic Leukemia. Advances in Chronic Lymphocytic Leukemia
133
150
.
Carsten U. Niemann, Jade Jones & Adrian Wiestner. 2013. Advances in Chronic Lymphocytic Leukemia. Advances in Chronic Lymphocytic Leukemia
259
291
.